Nemluvio (nemolizumab-ilto)
Eczema Agents Systemic Interleukin-13 (IL-13)Antag.mAb Subcutaneous Pen Injector (Ea)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Nemolizumab-ilto, a recombinant humanized immunoglobulin G2 (IgG2) monoclonal antibody, is an interleukin-31 (IL-31) receptor antagonist.
Nemolizumab-ilto is a humanized monoclonal IgG2 antibody, produced using recombinant DNA technology in Chinese Hamster Ovary cells. Nemolizumab is an interleukin-31 receptor alpha (IL-31RA) antagonist; the drug blocks IL-31 signaling by binding to IL-31RA, a naturally occurring cytokine involved in itching, inflammation, epidermal dysregulation, and fibrosis. Nemolizumab inhibits IL-31-induced responses, including the release of proinflammatory cytokines and chemokines.
After subcutaneous administration of multiple doses, nemolizumab exposure increases in an approximately dose-proportional manner over a dose range up to 30 mg; bioavailability decreases at higher dosages, decreasing by 9% with a dose of 60 mg and by 15% with a dose of 90 mg. Steady-state concentrations in patients with prurigo nodularis are achieved by 4 weeks in patients <90 kg and by 12 weeks in patients >=90 kg; in patients with atopic dermatitis, steady state is achieved by 4 weeks regardless of body weight. Following administration of a 60-mg dose, peak plasma concentrations of nemolizumab are achieved within approximately 6 days.
Exposure of nemolizumab decreases with increasing body weight. This difference in exposure is not expected to have a clinically important effect in patients with atopic dermatitis. In prurigo nodularis, however, decreased exposure in patients with higher body weight has a clinically significant impact on skin lesion response, necessitating weight-based dosing.
Age, renal impairment, and hepatic impairment do not appear to have clinically important effects on the pharmacokinetics of nemolizumab. The metabolic pathway of nemolizumab has not been characterized, but is expected to involve degradation into small peptides via catabolic pathways. The estimated terminal half-life of nemolizumab-ilto is 18.9 days.
USES: This medication is used to treat certain skin conditions (prurigo nodularis, atopic dermatitis). Nemolizumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking certain natural proteins in your body (interleukin-31) that may cause swelling, itching, and other skin problems.
Generic name: nemolizumab-ilto
Pronunciation: (NEE-moe-LIZ-ue-mab)
Drug class: Eczema Agents Systemic Interleukin-13 (IL-13)Antag.mAb
Therapeutic class: Dermatological
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Nemluvio
Indications
The following indications are listed for Nemluvio:
- Atopic Dermatitis
- Prurigo Nodularis
Also known as: Atopic Eczema, Disseminated Neurodermatitis, Hyde's Disease.
Dosing
No dosing information is available for this tab.
Administer nemolizumab-ilto by subcutaneous injection only.
Nemolizumab-ilto is available as a single-dose prefilled pen with a dual chamber containing 30 mg of lyophilized powder in one chamber and water for injection in the other chamber. The drug must be reconstituted prior to administration by activating the pen to mix the contents of the 2 chambers.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Nemluvio 30 Mg Pen | Maintenance | Inject 30 mg by subcutaneous route every 4 weeks rotating injection sites. |
No dosing information is available for this tab.
Drug interactions
Nemolizumab shows no clinically significant impact on the pharmacokinetics of the following cytochrome P-450 (CYP) substrates: midazolam (a CYP3A4/5 substrate), warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), metoprolol (a CYP2D6 substrate), and caffeine (a CYP1A2 substrate).
The manufacturer states that chronic inflammation can alter CYP enzyme formation due to increased cytokine levels (e.g., IL-1, IL-6, IL-10, tumor necrosis factor (TNF) alpha, interferon (IFN)). Nemolizumab may modulate cytokine levels, potentially influencing CYP enzyme activity. When initiating or discontinuing nemolizumab in patients receiving CYP substrates concomitantly, particularly those with a narrow therapeutic index (e.g., warfarin, cyclosporine), monitor drug effects (e.g., for warfarin) or concentrations (e.g., for cyclosporine) and adjust dosages as needed.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Selected Immunosuppressive Agents/Live Vaccines; Live Bcg
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: A variety of disease modifying agents suppress the immune system. Immunocompromised patients may be at increased risk for uninhibited replication after administration of live, attenuated vaccines or intravesicular BCG. Immune response to vaccines may be decreased during periods of immunocompromise.(1)
CLINICAL EFFECTS: The expected serum antibody response may not be obtained and/or the vaccine may result in illness.(1) After instillation of intravesicular BCG, immunosuppression may interfere with local immune response, or increase the severity of mycobacterial infection following inadvertent systemic exposure.(2)
PREDISPOSING FACTORS: Immunosuppressive diseases (e.g. hematologic malignancies, HIV disease), treatments (e.g. radiation) and drugs may all increase the magnitude of immunodeficiency.
PATIENT MANAGEMENT: The Centers for Disease Control(CDC) Advisory Committee on Immunization Practices (ACIP) states that live-virus and live, attenuated vaccines should not be administered to patients who are immunocompromised. The magnitude of immunocompromise and associated risks should be determined by a physician.(1) For patients scheduled to receive chemotherapy, vaccination should ideally precede the initiation of chemotherapy by 14 days. Patients vaccinated while on immunosuppressive therapy or in the 2 weeks prior to starting therapy should be considered unimmunized and should be revaccinated at least 3 months after discontinuation of therapy.(1) Patients who receive anti-B cell therapies should not receive live vaccines for at least 6 months after such therapies due to a prolonged duration of immunosuppression. An exception is the Zoster vaccine, which can be given at least 1 month after receipt of anti-B cell therapies.(1) The US manufacturer of abatacept states live vaccines should not be given during or for up to 3 months after discontinuation of abatacept.(2) The US manufacturer of live BCG for intravesicular treatment of bladder cancer states use is contraindicated in immunosuppressed patients.(3) The US manufacturer of daclizumab states live vaccines are not recommended during and for up to 4 months after discontinuation of treatment.(4) The US manufacturer of guselkumab states that live vaccines should be avoided during treatment with guselkumab.(5) The US manufacturer of inebilizumab-cdon states that live vaccines are not recommended during treatment and after discontinuation until B-cell repletion. Administer all live vaccinations at least 4 weeks prior to initiation of inebilizumab-cdon.(6) The US manufacturer of ocrelizumab states that live vaccines are not recommended during treatment and until B-cell repletion occurs after discontinuation of therapy. Administer all live vaccines at least 4 weeks prior to initiation of ocrelizumab.(7) The US manufacturer of ozanimod states that live vaccines should be avoided during and for up to 3 months after discontinuation of ozanimod.(8) The US manufacturer of siponimod states that live vaccines are not recommended during treatment and for up to 4 weeks after discontinuation of treatment.(9) The US manufacturer of ustekinumab states BCG vaccines should not be given in the year prior to, during, or the year after ustekinumab therapy.(10) The US manufacturer of satralizumab-mwge states that live vaccines are not recommended during treatment and should be administered at least four weeks prior to initiation of satralizumab-mwge.(11) The US manufacturer of ublituximab-xiiy states that live vaccines are not recommended during treatment and until B-cell recovery. Live vaccines should be administered at least 4 weeks prior to initiation of ublituximab-xiiy.(12) The US manufacturer of etrasimod states that live vaccines should be avoided during and for 5 weeks after treatment. Live vaccines should be administered at least 4 weeks prior to initiation of etrasimod.(13) The US manufacturer of emapalumab-lzsg states that live vaccines should not be administered to patients receiving emapalumab-lzsg and for at least 4 weeks after the last dose of emapalumab-lzsg. The safety of immunization with live vaccines during or following emapalumab-lzsg therapy has not been studied.(14) The US manufacturer of sibeprenlimab-szsi states live vaccines should not be given within 30 days prior to initiation or during treatment with sibeprenlimab-szsi.(15)
DISCUSSION: Killed or inactivated vaccines do not pose a danger to immunocompromised patients.(1) Patients with a history of leukemia who are in remission and have not received chemotherapy for at least 3 months are not considered to be immunocompromised.(1)
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Igg Antibodies And Derivatives/Efgartigimod-Alfa
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Efgartigimod-alfa binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of efgartigimod-alfa states that efgartigimod-alfa should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, efgartigimod-alfa should be discontinued.(3)
DISCUSSION: Clinical drug interaction studies with efgartigimod-alfa have not been performed. Efgartigimod-alfa may decrease concentrations of compounds that bind to the human FcRn.(3)
Igg Antibodies And Derivatives/Nipocalimab-Aahu
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Nipocalimab-aahu binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of nipocalimab-aahu states that nipocalimab-aahu should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, nipocalimab-aahu should be discontinued.(3)
DISCUSSION: Clinical drug interaction studies with nipocalimab-aahu have not been performed. Nipocalimab-aahu may decrease concentrations of compounds that bind to the human FcRn.(3)
Moderate Interaction: Assess the risk to the patient and take action as needed.
Igg Antibodies And Derivatives/Rozanolixizumab-Noli
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Rozanolixizumab-noli binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medications that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of rozanolixizumab-noli states that concurrent use with medications that bind to the human neonatal Fc receptor (FcRn) should be closely monitored for reduced effectiveness of these medications. If long-term use of such medications is essential for the patient, consider discontinuing rozanolixizumab-noli and use alternative therapies.(3)
DISCUSSION: Clinical drug interaction studies with rozanolixizumab-noli have not been performed. Rozanolixizumab-noli may decrease concentrations of compounds that bind to the human FcRn.(3)
Contraindications
*Known hypersensitivity to nemolizumab-ilto or any of the excipients in the formulation.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
- No disease contraindications
Adverse reactions
Atopic dermatitis: The most common adverse reactions (incidence >=1%) in patients with atopic dermatitis receiving nemolizumab-ilto in clinical studies were headache (including migraine), arthralgia, urticaria, and myalgia.
Prurigo nodularis: The most common adverse reactions (incidence >=1%) in patients with prurigo nodularis receiving nemolizumab-ilto in clinical studies were headache, atopic dermatitis, eczema, and eczema nummular.
Less Frequent
- Angioedema
More Frequent
- Eczema
- Headache disorder
Less Frequent
- Arthralgia
- Hypersensitivity drug reaction
- Myalgia
Rare or Very Rare
- Herpes zoster
- Injection site sequelae
- Urticaria
Precautions
No enhanced messaging available.
Atopic dermatitis: Clinical trials have demonstrated the safety and efficacy of nemolizumab-ilto, in combination with topical corticosteroids and/or topical calcineurin inhibitors, in pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis inadequately controlled by topical therapies. Evidence from two randomized, double-blind, placebo-controlled trials (ARCADIA 1 and ARCADIA 2) supports these findings. Safety and efficacy between pediatric and adults were similar
Prurigo nodularis: The safety and efficacy of nemolizumab-ilto for the treatment of prurigo nodularis have not been established in pediatric patients.
Data on the use of nemolizumab in pregnant women are insufficient to determine the risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Human IgG antibodies, including nemolizumab, cross the placenta increasingly throughout pregnancy, peaking in the third trimester. In a pre- and postnatal development study in cynomolgus monkeys, subcutaneous administration of nemolizumab-ilto during organogenesis through parturition led to increased early postnatal deaths at doses 36-50 times the maximum recommended human dose; however, the clinical relevance of this finding is unknown.
Because IgG antibodies can cross the placenta and may interfere with an infant's immune response, the risks and benefits of administering live vaccines to infants exposed to nemolizumab in utero should be carefully considered. Although the exact duration of drug persistence in infants is unknown, delaying live vaccines for at least 3 months after birth is recommended based on the half-life of nemolizumab-ilto and general principles of antibody transfer.
There are no data on the presence of nemolizumab in human milk, its effects on breastfed infants, or its impact on milk production. Nemolizumab has been detected in breast milk in monkeys, and maternal IgG and monoclonal antibodies are known to transfer into human milk. The effects of GI exposure and limited systemic exposure to the drug in breastfed infants are unknown. Consider the benefits of breastfeeding, the mother's need for nemolizumab, and any potential risks to the infant from the drug or the maternal condition.
The manufacturer states that no dosage adjustment is needed in geriatric patients.
Atopic dermatitis:In the clinical trials of patients with atopic dermatitis, 6% of patients in the primary safety population were >=65 years of age and 4.5% of patients in the long-term safety population were >=65 years of age. However, clinical studies did not include a sufficient number of older adults to determine if their response differs from that of younger patients.
Prurigo nodularis: In the OLYMPIA 1 and OLYMPIA 2 trials, 26.8% of patients were >=65 years of age. Long-term safety was evaluated in 26.2% of patients >=65 years of age. However, clinical studies did not include enough older adults to determine if their response differs from that of younger patients.
ICD codes
| Code | Type | Description |
|---|---|---|
| Atopic dermatitis | ||
| L20 | ICD10CM | Atopic dermatitis |
| L20.0 | ICD10CM | Besnier's prurigo |
| L20.8 | ICD10CM | Other atopic dermatitis |
| L20.81 | ICD10CM | Atopic neurodermatitis |
| L20.82 | ICD10CM | Flexural eczema |
| L20.84 | ICD10CM | Intrinsic (allergic) eczema |
| L20.89 | ICD10CM | Other atopic dermatitis |
| L20.9 | ICD10CM | Atopic dermatitis, unspecified |
| Prurigo nodularis | ||
| L28.1 | ICD10CM | Prurigo nodularis |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.